GlassScriptPhysician profile
Mohammed Q Khan
NPI 1912008087
$5,514.23
in general payments reported to CMS, 2019-2025
32 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $123 · 2021: $581 · 2022: $999 · 2023: $996 · 2024: $1,245 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.62 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $763.69 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $574.99 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $512.88 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $348.51 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $310.11 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $305.18 | 2020-2024 | Rayaldee |
| Ardelyx, INC. | $302.24 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $254.87 | 2022-2024 | |
| Glaxosmithkline, LLC. | $227.60 | 2021-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $200.84 | 2021-2024 | Lupkynis |
| Abbott Laboratories | $189.23 | 2025 | Pressurewire |
| Calliditas Therapeutics US INC. | $177.57 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $165.83 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $143.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $139.70 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $137.46 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.04 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $115.20 | 2019 | |
| Scpharmaceuticals INC. | $94.80 | 2025 | |
| Horizon Therapeutics Plc | $84.15 | 2019-2021 | |
| Baxter Healthcare | $72.15 | 2019 | |
| Bard Peripheral Vascular, INC. | $58.34 | 2019 | |
| Mallinckrodt Hospital Products INC. | $53.47 | 2022 | |
| Cmp Pharma, INC. | $52.40 | 2021 | |
| Fresenius USA Marketing, INC. | $39.47 | 2021-2023 | Velphoro |
| Alnylam Pharmaceuticals INC. | $22.76 | 2021 | |
| Lilly USA, LLC | $22.73 | 2024 | Jardiance |
| Medtronic, INC. | $17.56 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.